OBESITY

TIRZEPATIDE for the Treatment of Obesity

Population:  2539 Adults with obesity or overweight without type 2 diabetes.

Design: Double-blind, placebo-controlled.

Primary Outcome: Percentage of body weight reduction.

Tirzepatide helps adults with obesity lose weight and keep it off. It is proven to deliver significant and sustained weight loss.*†

*Along with diet and exercise.

In a 72-week study of adults without diabetes, average weight loss was 15.0% (15.4 kg) for 5 mg, 19.5% (20 kg) for 10 mg, 20.9% (21.8 kg) for 15 mg, and 3.1% (3.2 kg) for placebo. Average starting weights were 103 kg for 5 mg, 106 kg for 10 mg, 106 kg for 15 mg, and 104 kg for placebo.

5 clinical trials demonstrated significant weight reduction

The chart comparing the effectiveness of Tirzepatide (in various doses) to Placebo, Insulin Semaglutide, Insulin Degludec, Insulin Glargine and Basal insulin+ Metformin in lowering weight in adults with type 2 diabetes.

Key findings: Tirzepatide at all doses (5 mg, 10 mg and 15 mg) demonstrated significantly greater weight reduction compared to Placebo, Insulin Semaglutide, Insulin Degludec, Insulin Glargine and Basal insulin+ Metformin.

This indicates that Tirzepatide might be a more effective treatment option for achieving better weight reduction in patients with type 2 diabetes.